Calamos Wealth Management LLC Increases Holdings in Danaher Corporation (NYSE:DHR)

Calamos Wealth Management LLC lifted its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 17.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,333 shares of the conglomerate's stock after buying an additional 10,408 shares during the quarter. Danaher comprises 0.7% of Calamos Wealth Management LLC's portfolio, making the stock its 28th largest position. Calamos Wealth Management LLC's holdings in Danaher were worth $14,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. raised its stake in shares of Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after purchasing an additional 99 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in shares of Danaher during the 4th quarter valued at about $27,000. Smallwood Wealth Investment Management LLC bought a new position in shares of Danaher in the first quarter worth approximately $31,000. Rialto Wealth Management LLC bought a new position in shares of Danaher in the fourth quarter worth about $34,000. Finally, Hurley Capital LLC purchased a new position in Danaher in the 4th quarter worth approximately $34,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president owned 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.20% of the company's stock.

Danaher Price Performance

NYSE DHR traded down $3.60 during trading hours on Monday, reaching $199.60. The company's stock had a trading volume of 2,388,352 shares, compared to its average volume of 3,495,257. The firm has a market capitalization of $142.85 billion, a price-to-earnings ratio of 38.76, a P/E/G ratio of 2.85 and a beta of 0.77. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70. The company's 50-day moving average is $195.63 and its two-hundred day moving average is $207.10. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. On average, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.64%. Danaher's dividend payout ratio (DPR) is 24.85%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. JPMorgan Chase & Co. decreased their price objective on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. Guggenheim reissued a "buy" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Robert W. Baird cut their price target on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Wolfe Research lowered their target price on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a report on Monday, April 7th. Finally, Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Danaher has an average rating of "Moderate Buy" and a consensus target price of $248.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.